Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential

Core Insights - Creative Medical Technology Holdings, Inc. supports President Trump's executive order to expand access to in vitro fertilization (IVF), aligning with its OvaStem® program which shows an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient's own eggs [1][4] Group 1: Company Overview - Creative Medical Technology Holdings, Inc. is a biotechnology company focused on regenerative medicine, particularly in reproductive health through its OvaStem® program [1][5] - The company has filed for Orphan Drug Designation for Primary Ovarian Insufficiency (POI), highlighting its commitment to fertility innovation [2] Group 2: OvaStem® Program - OvaStem® offers a personalized alternative to traditional IVF by utilizing a patient's own cells, significantly improving the chances of conception for patients with POI, who typically have only a 5-10% chance of spontaneous pregnancy [2] - The next-generation OvaStem® integrates the AlloStem® platform, which is currently involved in two FDA-cleared clinical trials [2] Group 3: Executive Order Impact - The executive order mandates recommendations to lower out-of-pocket IVF costs, which currently range from $12,000 to $25,000 per cycle, potentially increasing access to advanced fertility technologies [3] - The administration's plan aims to remove financial barriers, facilitating greater adoption of fertility treatments [3] Group 4: Leadership Statements - The President and CEO of Creative Medical Technology Holdings expressed enthusiasm for the executive order, emphasizing the company's expertise in regenerative medicine and its potential to redefine reproductive health [4] - The Director of Clinical Operations highlighted the goal of providing safe, effective, and affordable infertility solutions, positioning OvaStem® at the forefront of this movement [4] Group 5: Future Commitment - Creative Medical Technology Holdings is committed to advancing innovative solutions in regenerative medicine, aiming to empower families and enhance shareholder value as federal efforts to expand fertility care progress [4]